文献速递药物不良反应与药物警戒

药物警戒中的病例识别框架:并非所有报告都等同

Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal.
PubMed 文献 · Drug Saf · 2026-10-23

该研究开发了一个结构化框架,用于区分编码药物-事件共现检索出的候选报告与有临床意义的病例。通过药物诱导冲动性和药物诱导自杀倾向两个案例研究,框架在信息丰富和常规审查条件下应用。结果显示,在案例1中,无明确因果证据的药物非相关报告比例(约20-40%)高于有既定因果作用的药物(4%);在案例2中,69%报告被分类为非相关,17%为不可评估。

要点

  • 检索不等于病例识别,需评估暴露、事件、关系及背景的相关性。
  • 无明确因果证据的药物非相关报告比例更高(约20-40% vs 4%)。
  • 框架可系统化区分相关、非相关和不可评估报告,提高透明度。

核心结论

  • 药物警戒中检索不等同于病例识别,相关性取决于暴露、事件、关系及背景是否与临床问题对应。

研究设计与样本

  • 序贯框架开发研究,使用两个案例研究:药物诱导冲动性(信息丰富条件)和药物诱导自杀倾向(常规审查条件)。

主要发现

  • 案例1中,无明确因果证据的药物非相关报告频率约20-40%,而有既定因果作用的药物为4%。
  • 案例1中,保留为相关的报告进一步通过报告者怀疑和证据限定词表征,明确怀疑的报告更常包含支持性限定词。
  • 案例2中,框架将69%的报告分类为非相关,17%为不可评估。

关键数值与推荐

  • 框架评估相关性涵盖暴露、事件、药物-事件关系及环境/人群四个方面。

临床怎么用

  • 在药物警戒分析中应使用结构化框架明确病例定义和裁定过程,避免将异质报告混合导致误解。

局限性

  • 需要独立评估框架的可重复性和可移植性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrieval of adverse event reports based on coded drug-event co-occurrence enables large-scale pharmacovigilance analyses but yields candidate reports rather than clinically adjudicated cases. Without explicit case identification, heterogeneous reports may be combined within the same case series and misinterpreted in downstream analyses. AIM: The aim of the study was to develop a structured framework for distinguishing clinically meaningful cases from candidate reports retrieved through coded drug-event co-occurrence, and to illustrate its application across information-rich and routine-review conditions. METHODS: We conducted a sequential framework-development study using two case studies. Drug-induced impulsivity was used to iteratively develop and refine the framework under information-rich conditions. Drug-induced suicidality was used to examine its application under routine-review conditions with variable information availability and explicit classification of nonassessability. RESULTS: In case 1, nonrelevant reports were more frequent for drugs with uncertain or no established evidence (~ 20-40%) than for drugs with established causal roles (4%). The framework assessed relevance across exposure, event, the drug-event relationship, and setting/population. Reports retained as relevant were further characterized by reporter suspicion and evidentiary qualifiers supporting or weakening suspicion. Reports with explicit suspicion more often contained supportive qualifiers. In case 2, application of the framework classified 69% of reports as nonrelevant and 17% as nonassessable. CONCLUSIONS: In pharmacovigilance, retrieval is not equivalent to case identification. Relevance depends on whether exposure, event, their relationship, and context correspond to the clinical question being investigated. Explicit case definitions and transparent adjudication make this distinction systematic and auditable. Independent evaluation of the framework is needed to establish its reproducibility and transferability across pharmacovigilance questions.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Fusaroli M, China JF, Sartori D, et al. Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal. Drug Saf. 2026. PMID: 42909775. doi:10.1007/s40264-026-01743-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。